Sterile Filtration Of Budesonide As A Preferred Sterilization Strategy

Sterile budesonide is recognized as a high-integrity option for inhalation products because of its strong local therapeutic activity and the especially stringent sterility expectations associated with pulmonary delivery. The document explains that conventional terminal sterilization methods are often unsuitable for budesonide, as the molecule is highly sensitive to heat, oxygen, radiation, and mechanical stress. These conditions can trigger degradation, impurity formation, and changes in particle size — concerns repeatedly highlighted in the patent literature, including statements noting that “exposure to elevated temperatures, oxygen, ionizing radiation…results in significant degradation.”

Although moist-heat sterilization has been widely patented, it still depends on carefully controlled processing conditions to minimize product damage. Alternative technologies such as nanoparticulate filtration, high-temperature short-time (HTST) processing, dry heat, and supercritical CO₂ sterilization each offer specific advantages, but they also introduce technical complexity, scalability concerns, or regulatory challenges that can limit broader application.

Curia instead utilizes sterile filtration, a non-thermal and well-established regulatory approach that removes microorganisms without exposing the API to damaging conditions. The process includes dissolution, bioburden reduction, sterilizing-grade 0.22 µm filtration under Grade A conditions, and aseptic crystallization. As described in the document, the process uses “final sterilization using a validated sterilizing-grade 0.22 µm membrane filter,” enabling sterility assurance while maintaining the chemical integrity and physical characteristics of the budesonide.